Trial · NCT02688270
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
NCT02688270, Phase 2, Completed, Covis Pharma S.à.r.l.; results first posted 2022-11-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon. Trials, record NCT02688270. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02688270
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
- NCT number
- NCT02688270
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 65 participants, actual
- Lead sponsor
- Covis Pharma S.à.r.l.
- Conditions
- Raynaud's Phenomenon Secondary to Connective Tissue Disease
- Interventions
- Vascana (0.9% nitroglycerin cream), Vehicle Cream (placebo)
- First posted
- 2016-02-23
- Last updated
- 2022-11-02
- Results first posted
- 2022-11-02
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Raynaud's Symptom Severity (Change From Baseline) | 6 weeks | Change from baseline to visit 6 in peak Main Raynaud's Symptom (MRS) severity. Raynaud's symptoms will be assessed separately using a 0 to100-mm Visual Analog Scale (VAS) for pain, numbness, and tingling where 0 mm = no symptom and 100 mm = most severe symptom. |
| Primary | Raynaud's Symptom Severity (Percentage of Responders) | 6 weeks |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Raynaud's Symptom Severity (Change From Baseline) | 6 weeks | score on a scale | LEAST_SQUARES_MEAN | |
| PRIMARY | Raynaud's Symptom Severity (Percentage of Responders) | 6 weeks | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Raynaud's Symptom Severity (Change From Baseline) | Vascana | -20.19 | 95% Confidence Interval -26.63 to -13.75 | score on a scale | |
| Raynaud's Symptom Severity (Change From Baseline) | Vehicle Cream | -18.63 | 95% Confidence Interval -25.07 to -12.19 | score on a scale | |
| Raynaud's Symptom Severity (Percentage of Responders) | Vascana | 37 | Participants | ||
| Raynaud's Symptom Severity (Percentage of Responders) | Vehicle Cream | 29 | Participants |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment Sequence A | 16 | |
| Overall Study | STARTED | Treatment Sequence B | 16 | |
| Overall Study | STARTED | Treatment Sequence C | 17 | |
| Overall Study | STARTED | Treatment Sequence D | 16 | |
| Overall Study | COMPLETED | Treatment Sequence A | 16 | |
| Overall Study | COMPLETED | Treatment Sequence B | 16 | |
| Overall Study | COMPLETED | Treatment Sequence C | 17 | |
| Overall Study | COMPLETED | Treatment Sequence D | 16 | |
| Overall Study | NOT COMPLETED | Treatment Sequence A | 0 | |
| Overall Study | NOT COMPLETED | Treatment Sequence B | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events16
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Vascular disorders | Vascana | 0 | 17 | 0 |
| other | Hypertension | Vascular disorders | Vehicle Cream | 1 | 16 | 1 |
| other | Blood Pressure Increased | Vascular disorders | Vascana | 1 | 17 | 1 |
| other | Blood Pressure Increased | Vascular disorders | Vehicle Cream | 2 | 16 | 2 |
| serious | Blood Pressure Increased | Vascular disorders | Vascana | 8 | 65 | 8 |
| serious | Blood Pressure Increased | Vascular disorders | Vehicle Cream | 7 | 65 | 7 |
| serious | Nervous System Disorders | Nervous system disorders | Vascana | 1 | 65 | 1 |
| serious | Nervous System Disorders | Nervous system disorders | Vehicle Cream | 4 | 65 | 4 |
| serious | General disorders and administration site conditions | General disorders | Vascana | 3 | 65 | 3 |
| serious | General disorders and administration site conditions | General disorders | Vehicle Cream | 1 | 65 | 1 |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Vascana | 0 | 65 |
| Total, all-cause mortality | Vehicle Cream | 0 | 65 |
| Total, other adverse events | Vascana | 1 | 17 |
| Total, other adverse events | Vehicle Cream | 3 | 16 |
| Total, serious adverse events | Vascana | 17 | 65 |
| Total, serious adverse events | Vehicle Cream | 16 | 65 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Vascana vs Vehicle Cream: Raynaud's Symptom Severity (Percentage of Responders) | Trial comparisons |
| Vascana vs Vehicle Cream: deaths from any cause | Trial comparisons |
| Vascana vs Vehicle Cream: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02688270
GET https://conductscience.org/api/trials/v1/NCT02688270/registered